Search Results
May 25, 2026, 08:06 ET Menarini Group annonce de nouvelles données lors de la réunion annuelle 2026 de l'American Society of Clinical Oncology (ASCO)
Therapeutics, présentera un exposé oral de dernière minute sur l'essai de phase 3 SENTRY portant sur le selinexor chez des patients atteints de myélofibrose (MF) n'ayant jamais eu recours à la JAKi. Selinexor est commercialisé aux États-Unis par Karyopharm Therapeutics et dans l'Union européenne par Stemline.«Les
More news about: Menarini Industrie Farmaceutiche Riunite
May 25, 2026, 08:03 ET Menarini Group Anuncia Novos Dados na Reunião Anual da American Society of Clinical Oncology (ASCO) 2026
Karyopharm Therapeutics, apresentará uma apresentação oral tardia do estudo SENTRY de fase 3 de selinexor em pacientes virgens de JAKi com mielofibrose (MF). O Selinexor é comercializado nos EUA pela Karyopharm Therapeutics e na UE pela Stemline."Os extensos dados oncológicos que serão apresentados,
More news about: Menarini Industrie Farmaceutiche Riunite
May 25, 2026, 07:46 ET El Grupo Menarini anuncia nuevos datos en la Reunión Anual de la Sociedad Estadounidense de Oncología Clínica (asco) 2026
presentará una presentación oral de última hora del ensayo SENTRY de fase 3 de selinexor en pacientes sin tratamiento previo con JAKi con mielofibrosis (MF). Selinexor es comercializado en los EE. UU. por Karyopharm Therapeutics y en la UE por Stemline."Los amplios datos oncológicos que se presentarán,
More news about: Menarini Industrie Farmaceutiche Riunite
May 25, 2026, 06:44 ET Menarini Group Announces New Data at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
Karyopharm Therapeutics, will present a late-breaking oral presentation from the phase 3 SENTRY trial of selinexor in JAKi naïve patients with myelofibrosis (MF). Selinexor is marketed in the U.S. by Karyopharm Therapeutics, and in the EU by Stemline."The extensive oncology data that will be presented,
More news about: Menarini Industrie Farmaceutiche Riunite
May 21, 2026, 16:30 ET MFI Received Nasdaq Notification Regarding Filing Rule Deficiency
HONG KONG, May 21, 2026 /PRNewswire/ -- mF International Limited (NASDAQ:MFI) ("mF International" or the "Company"), today announced that it has received written notification (the "Notification Letter") from The Nasdaq Stock
More news about: mF International Limited
May 18, 2026, 10:01 ET Dairy Processing Equipment Market to reach US$ 19.1 billion by 2033, Accelerates as Automation Transforms Dairy Production - Persistence Market Research
Dairy Filtration Systems Market by Filtration Type (Reverse Osmosis (RO), Ultrafiltration (UF), Microfiltration (MF), Nanofiltration (NF), Cross-flow Filtration), by Module Design (Spiral Wound, Tubular, Plate & Frame, Hollow Fiber), Application (Processed Milk,
More news about: Persistence Market Research Pvt. Ltd.
May 14, 2026, 07:30 ET Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment
webcast will be available on the Company's website approximately two hours after the event.About the Phase 3 SENTRY TrialSENTRY (XPORT-MF-034;
More news about: Karyopharm Therapeutics Inc.
May 12, 2026, 13:15 ET TAIYO YUDEN Launches New Metal Power Inductors Combining Advanced Performance with a Smaller Size
inductors in its MCOIL™ LSCN series, available in four sizes. The new lineup includes the "LSCND0805FET1R2MJ" (0.8 x 0.45 x 0.65 mm) and the "LSCND1008HKT1R5MF" (1.0 x 0.8 x 0.80 mm).
More news about: TAIYO YUDEN (U.S.A.) INC
May 12, 2026, 08:03 ET Halia Therapeutics to Present Final Phase 2 Ofirnoflast Data in Lower-Risk MDS at EHA2026 and Announces Appointment of Han Myint, MD, FACP, as Chief Medical Officer
Myeloid Franchise Team, where he contributed to the development, approval, and global launch of therapies for myeloid diseases including Thalassemia, MF, MDS and AML.Before transitioning to industry, Dr. Myint was an academic hematologist-oncologist and stem cell transplant physician. He served
More news about: Halia Therapeutics
May 06, 2026, 15:20 ET Hexaware Reports Q1CY26 Revenue at USD 388.5 Mn, Up 4.6% YoY Q1CY26 EPS at INR 5.77, Increase of 7.2% YoY
in the utilization computation after the completion of an initial training period of up to four months. (4) This includes restricted cash balance and MF investments (5) Exchange rate used is 94.84.Financial Performance
More news about: Hexaware Technologies Ltd
May 06, 2026, 15:13 ET Hexaware Reports Q1CY26 Revenue at USD 388.5 Mn, Up 4.6% YoY Q1CY26 EPS at INR 5.77, Increase of 7.2% YoY
in the utilization computation after the completion of an initial training period of up to four months. (4) This includes restricted cash balance and MF investments (5) Exchange rate used is 94.84.Financial Performance
More news about: Hexaware Technologies Ltd
May 01, 2026, 04:21 ET Dreame Launches Three World-First Air and Environmental Products at DREAME NEXT, Marking North American Expansion
showcase in San Francisco. The lineup includes the FP10 Air Purifier, built around the world's first roller self-cleaning system for pet households. The MF10 Bladeless Fan, which has already claimed the #1 New Release spot on Amazon, and the Dreame Halo, a three-in-one fan,
More news about: Dreame Technology
Apr 28, 2026, 07:30 ET Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma
utility of longer treatment times (Study RW-HPN-MF-01), the
More news about: SOLIGENIX, INC.
Apr 27, 2026, 11:15 ET /C O R R E Ç Ã O -- Odds Scanner Group/
conjunto completo de ferramentas de comparação de odds do Odds Scanner, com monitoramento de preços em tempo real entre operadores autorizados pela SPA/MF, informações sobre bônus e promoções do mercado brasileiro, guias específicos e a cobertura editorial do grupo vinda de outros mercados. A plataforma
More news about: Odds Scanner Group
Apr 24, 2026, 06:00 ET FLAGSTAR BANK POSTS SECOND CONSECUTIVE QUARTER OF PROFITABILITY REPORTING FIRST QUARTER 2026 NET INCOME ATTRIBUTABLE TO COMMON STOCKHOLDERS OF $0.03 PER DILUTED SHARE AND ADJUSTED NET INCOME ATTRIBUTABLE TO COMMON STOCKHOLDERS OF $0.04 PER DILUTED SHARE
million or 6%Total MF/CRE exposure down $1.6 billion or 4%Multi-family loans down $1.1 billion or 4%
More news about: Flagstar Bank, N.A.
Apr 22, 2026, 08:05 ET IMAAVY® (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG)
Acquired myasthenia gravis in childhood. Curr Opin Neurol. 2010 Oct;23(5):536-40. doi: 10.1097/WCO.0b013e32833c32af.xviii Finnis MF, Jayawant S. Juvenile myasthenia gravis: a paediatric perspective. Autoimmune Dis. 2011;2011:404101. doi: 10.4061/2011/404101.xix Haliloglu
More news about: Johnson & Johnson
Apr 22, 2026, 02:46 ET NEW TELE-DENTISTRY PROGRAMME SUPPORTS EARLY INTERVENTION FOR CHILDREN AT RISK OF CARIES
[1] Hu S, Sim YF, Toh JY, Saw SM, Godfrey KM, Chong YS, Yap F, Lee YS, Shek LP, Tan KH, Chong MF, Hsu CS. Infant dietary patterns and early childhood caries in a multi-ethnic Asian cohort. Sci Rep. 2019 Jan 29;9(1):852. doi: 10.1038/s41598-018-37183-5.
More news about: National University Health System (NUHS)
Apr 21, 2026, 12:00 ET Manulife Wealth and Asset Management's Retail Channel Establishes Dedicated Alternative Investments Distribution Team to Work Directly with Financial Advisors
contact:Elizabeth [email protected] MF5401764 4/26
More news about: Manulife Wealth & Asset Management
Apr 21, 2026, 10:32 ET Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Selected for Late-Breaking Oral Presentation at ASCO 2026 Annual Meeting
"Publications and Presentations" in the Investor section of the Company's website.About the Phase 3 SENTRY TrialSENTRY (XPORT-MF-034;
More news about: Karyopharm Therapeutics Inc.
Apr 21, 2026, 08:00 ET Vacancy climbs as Canadian rent growth hits 4-year low
https://mma.prnewswire.com/media/2961230/CND_MF_Report_Q1_2026_Social_Video.mp4Logo - https://mma.prnewswire.com/media/2447766/5927358/Yardi_Logo.jpg
More news about: Yardi
Apr 14, 2026, 12:34 ET Meshy AI Announces Integration with Formlabs to Bridge the Gap Between Generative AI and Professional 3D Manufacturing; Debuts at RAPID + TCT 2026
month.Frequently Asked QuestionsQ: What file formats does Meshy export for 3D printing? Meshy exports STL, OBJ, GLB, FBX, and 3MF formats — covering the full range of formats accepted by professional slicers including Bambu Studio, PrusaSlicer, Cura, OrcaSlicer, and Netfabb.Q:
More news about: Meshy
Apr 02, 2026, 07:30 ET Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy
utility of longer treatment times (Study RW-HPN-MF-01), the
More news about: SOLIGENIX, INC.
Mar 30, 2026, 05:23 ET AI邂逅東方養生智慧：FoodTrack突破卡路里計數 重塑健康管理理念
PolyVentures簡介：https://www.polyu.edu.hk/kteo/entrepreneurship/start-ups/polyu-start-ups-list/mf/2024/bay-technologies-limited/紅點設計獎項目頁面：
More news about: Bay Technologies
Mar 24, 2026, 07:00 ET Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume Reduction
webcast will be available on the Company's website approximately two hours after the event.About the Phase 3 SENTRY TrialSENTRY (XPORT-MF-034;
More news about: Karyopharm Therapeutics Inc.
Mar 23, 2026, 07:30 ET HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026
Phase 2 Investigator-Initiated Real-World Study Evaluating Topical Hypericin Ointment Photodynamic Therapy for Early-Stage Mycosis Fungoides/CTCL (RW-HPN-MF-01) presented by Dr. Ellen Kim, Director, Penn Cutaneous Lymphoma Program, Vice Chair of Clinical Operations, Dermatology Department, and Professor
More news about: Soligenix